On June 23, BeOne Medicines rose 3.04% in regular trading, trading at 166.1 HKD/share, with turnover of 49.29 million HKD. The stock rebounded after falling over 3% in the previous session alongside a broad biotech sector pullback.

On the news front, BeOne Medicines recently announced that the U.S. FDA accepted its New Drug Application for Tevimbra targeting esophageal squamous cell carcinoma, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, signaling continued fundamental improvement.

Within the Biotechnology sector, the overall sector partially recovered today. Among individual stocks, AKESO up 3.44%, REMEGEN up 3.15%, CARSGEN-B up 1.55%, INNOVENT BIO up 1.26%, providing sector linkage support for the technical rebound in BeOne Medicines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)